We report measurements of chemical concentrations in clinical blood serum and urine samples using liquid-core optical fiber (LCOF) Raman spectroscopy to increase the collected signal strength. Both Raman and absorption spectra were acquired in the near-infrared region using the LCOF geometry. Spectra of 71 blood serum and 61 urine samples were regressed via partial least squares against reference analyzer values. Significant correlation was found between predicted and reference concentrations for 13 chemicals. Using absorption data to normalize the LCOF enhancement made the results more accurate. The experimental geometry is well suited for high-volume and automated chemical analysis of clear biofluids.
Introduction
Biofluids, including blood, urine, lymph, and saliva, provide rich information on human health status. Every year approximately 600 million cholesterol tests are performed worldwide to monitor cardiovascular disease. More than 100 million diabetics need to monitor their blood glucose level. 1 In the United States, more than 300 million urine analyses are performed to help diagnose kidney, urinary, and other diseases. 2 Standard clinical laboratory analyzers employ an array of sensors, each measuring one chemical in a separate subvolume. Because the detection is performed using enzymes and electrodes, the sample cannot be used again for other measurements. Development of reagentless, multichemical sensors could have significant impact in high-throughput arenas such as primary care facilities, hospitals, and screening of military and inmate populations.
Multiwavelength spectroscopic methods are sensitive to multiple chemicals. Among these methods, mid-infrared (mid-IR) spectroscopy, near-infrared (NIR) spectroscopy, and Raman spectroscopy are all intrinsically reagentless and have been explored for chemical analysis of biofluids, each presenting experimental challenges. Mid-IR spectroscopy has been used for concentration measurements in blood serum samples [3] [4] [5] [6] [7] and urine samples. 8, 9 In the mid-IR region, the measurement accuracy is limited by the strong water absorption background. Usually preprocessing is required to dry the sample prior to the measurement to remove the dominant water background for better accuracy. To avoid the water dominant region, NIR spectroscopy has been applied to biofluids including blood serum samples 10 -13 and urine samples. 14 Though it requires no preprocessing, the method is limited by relatively broad peaks that are hard to resolve when overlapped. NIR Raman spectroscopy, which is of interest in this paper, has also been used to predict chemical concentrations in blood serum samples 1, 7, [15] [16] [17] [18] and urine samples. 2, 19, 20 A major limitation, however, is the weakness of the Raman signal.
The use of liquid-core optical fiber (LCOF) geometry can enhance the collected Raman signal from nonturbid aqueous samples by 1 or 2 orders of magnitude. 20 -24 In this approach, the liquid sample resides within a thin tube of lower refractive index. A waveguide is thus formed, increasing the interaction length and guiding emitted light to a common exit point. Because the entire sample volume is illuminated, the fluorescence quenching rate also typically increases, further improving the Raman signal-tonoise ratio. The linearity between Raman intensity and chemical concentration is distorted in a LCOF, however, because the collection enhancement is absorption dependent. 25, 26 To correct this effect, we recently augmented a LCOF system to measure a sample's absorption coefficient in the LCOF as well. 26 With this information and a characterization of scattering losses within the LCOF, a 60% variance in 890 cm Ϫ1 Raman peak areas from 20% aqueous ethanol was reduced to 1% in a set of samples with different concentrations of India ink.
Such a correction method is relevant for LCOF Raman spectroscopy of biofluids. We estimate, using spectrophotometer-based absorption measurements on a group of urine samples, that LCOF enhancement can vary sample to sample by 20% in our present setup. In clinical measurements, particularly in blood serum, such an uncertainty in prediction would not be acceptable for many analytes. Removing this source of error would be essential for clinical applications.
The purpose of the work presented here was twofold. The first goal was to perform the first LCOFbased Raman spectroscopy for quantification of analyte concentrations in biofluids. The second was to establish whether enhancement-correction methods improve the prediction accuracy. Relationships between integration time, sample set size, reference analyzer accuracy, and prediction accuracy were studied as well.
Materials and Methods

A. Instrumentation
An instrumentation sketch is shown in Fig. 1 ; detailed information can be found in previous publications. 20, 24, 26 Briefly, the biofluid sample resides within the LCOF and is illuminated sequentially by an 830 nm laser L and a broadband thermal source W through fiber OF 1 . Backscattered Raman and transmitted white-light spectra are recorded over the same wavelength range by a spectrograph and CCD detector. Two additional fibers reside in the far end of the LCOF: OF 2 guides the light from the LCOF to a powermeter (PM) for calculation of the absorption coefficient at the laser wavelength, and OF 3 sends the transmitted laser light to a spectrometer (Ocean Optics, Dunedin, Florida) to monitor possible laser peak changes during the experiment.
The LCOF was made of Teflon-AF (DuPont) and manufactured by Biogeneral, Incorporated (San Diego, California). The length of the LCOF was 30 cm, with inner and outer diameters of 600 and 800 m; the total volume was therefore less than 0.1 ml. Laser power was approximately 160 mW at the entrance to the LCOF. The spectral resolution was approximately 7 cm Ϫ1 as determined using neon emission lines. The Raman resolution was no worse than 13 cm Ϫ1 as determined by the 1004 cm Ϫ1 phenylalanine peak.
B. Materials and Methods
Blood serum and urine samples were collected from previously obtained clinical specimens in the University of Rochester Medical Center with donor identification removed. Eighty blood serum samples were collected in 4 days at a rate of 20 per day. During the 9 to 14 days that elapsed between the clinical reference concentration measurement and the Raman experiment, the samples were refrigerated at 4°C. Eighty urine samples were collected in 1 week, at a rate of 10 to 20 samples per day. In this case, 2 to 8 days elapsed between reference and Raman measurements. An ADVIA 2400 Chemistry System (Research Triangle Park, North Carolina) provided reference values for the 13 chemicals discussed here (11 in blood serum and 2 in urine). Table 1 
C. Spectrum Acquisition
Samples were used as received. The samples were injected into the LCOF system by a 1 ml syringe slowly and steadily to minimize the formation of air bubbles, which scatter light and thus degrade LCOF performance. In the urine experiment, three injections of 1 ml each ͑10ϫ the volume of the LCOF) were made for each sample; the first two injections were to flush possible residue. Additional tubing, not shown in Fig. 1 , carries the flushed LCOF contents to a waste container. In the blood serum experiment, since most samples were small in volume (1-2 ml), only one injection could be done for each sample; holdover from the previous injection did not appear to cause a problem. Samples with visible turbidity (n ϭ 3 for blood serum samples, n ϭ 7 for urine samples) or samples with Ͻ1 ml volume (i.e., less than the syringe volume) (n ϭ 2 for blood serum samples) were discarded. For each sample, the Raman spectrum was taken first, followed quickly by the white-light spectrum to minimize possible sample changes. In the blood serum study, Raman spectra were integrated for 60 frames of 3 s each, and white-light spectra for a single frame of 30 s. In the urine study, both the Raman and the white-light spectra were integrated for 40 frames of 2 s each. In total, 75 blood serum spectra and 73 urine spectra were recorded for both Raman and white light.
Both spectral experiments were finished in 2 days, with approximately 40 sample runs each day. Realignment was done between the 2 days to minimize system drift. The system was aligned by maximizing the 890 cm Ϫ1 Raman peak intensity from a 20% aqueous ethanol solution.
D. Data Processing
All the Raman spectra were corrected for CCD readout noise and cosmic ray artifacts, Savitzky-Golay smoothed 27 (FWHM Ϸ14 cm
Ϫ1
) and throughput corrected versus wavelength using a broad white-light spectrum. Ten frames were removed from each blood serum spectrum and eight frames were removed from each urine spectrum to eliminate cosmic rays, leaving a total integration time of 150 s for blood serum and 64 s for urine. Fluorescence was mathematically subtracted by a fifth-order polynomial via a least-squares fit, prioritizing reproducibility over nonnegativity in the residual (though a nonnegativity-constrained polynomial fit of the same order 28 produced similar quantitative results and is used for presentation in figures). This processing produced an initial or "direct" Raman spectrum. The direct Raman intensity is a function of the sample's absorption coefficient a because the LCOF enhancement scales with penetration depth into the sample. Using the corresponding absorption spectra, we additionally computed a "corrected" Raman spectrum via 26
where L is the LCOF length, aR ͑͒ and aL are the absorption coefficients at the Raman-shifted and laser wavelengths, and s describes scattering loss per unit length due to tubing imperfections. P͑͒ corrected is designed to be insensitive to the variations in LCOF enhancement experienced by different samples.
To apply Eq. (1), the tubing scattering coefficient s needs to be known. It can be measured directly using an optical fiber insertion method 29 or estimated by optimizing the prediction results for one chemical using Eq. (1) . In previous studies, we found the approaches gave similar values of s . 26 Here we calculated s by optimizing predictions of blood urea nitrogen (BUN) in blood serum samples and urine urea nitrogen (UUN) in urine samples, arriving at values of 0.005 and 0.007 mm
, respectively. The same optimized s value was then used for all the chemicals in the sample set; i.e., s was not a free parameter for each chemical. (Separate optimizations on a chemical-by-chemical basis yielded similar s values, within 20%. The effect of this variation upon prediction accuracy was small; overall, applying the maximum or minimum s value changed prediction accuracies for all chemicals by less than 2.5%.) For comparison, the mean absorption coefficient at the laser wavelength was 0.006 mm Ϫ1 for blood serum and 0.0033 mm Ϫ1 for urine. The probable reason for the difference in s values is that small air bubbles are easier to generate when injecting urine samples, because it is less viscous than blood serum. Attached to the LCOF inner surface, these bubbles increase the surface scattering loss. This contributes to an increased s for urine samples.
A student t test based on Mahalanobis distance 30 was used to reject spectra with 95% probability of being spectral outliers ͑p Ͻ 0.05͒. All blood serum spectra were accepted, but 12 urine spectra were flagged as outliers. Visual inspection confirmed that these spectra exhibited unique spectral features, either Raman peaks or fluorescence background trends. Because the role of urine is to excrete chemicals, the appearance of more outliers than for blood serum is unsurprising, particularly in a small data set. In total 71 blood serum spectra and 61 urine spectra qualified for further processing.
Both direct and corrected spectra were processed using partial least-squares (PLS) 31, 32 leave-one-out cross validation. For each chemical, one spectrum at a time was left out and predicted using the PLS model built by the remaining spectra and concentration information. The root-mean-squared error of cross validation (RMSECV) was calculated for each chemical twice, using first direct and then corrected Raman spectra. Spectral range was varied for each chemical to minimize the corresponding RMSECV.
Since different chemicals have different physiological concentration levels and ranges, RMSECV alone is a poor metric for the clinical usefulness of the predictions. r 2 , defined as the square of the correlation coefficient between the reference concentration and the predicted concentration, is also imperfect because it cannot detect when the predicted reference concentration slope is less than unity as long as there is a linear correlation between them, as often happens when calibration data are weak. To classify the overall prediction quality, we ratio the RMSECV to the spread in concentrations within the sample set, defining a coefficient g as the "goodness of prediction":
As mentioned, STD R is the standard deviation of the chemical concentration in the sample population. g specifies the number of resolvable concentration bins into which the middle 2͞3 of the population can be placed by the PLS predictions. A value of unity means the prediction error spans the entire physiological range; larger values of g denote more and more useful concentration accuracy. We take g Ն 2 as a rough cutoff for a "good" prediction, noting that all analyte concentrations in this particular study lay in the physiologically healthy range except for a few elevated glucose levels. g was calculated using both direct and corrected Raman spectra.
To study the dependence of prediction error upon spectral shot noise, predictions were performed using spectra corresponding to different integration times. Specifically, for blood serum samples, calibration spectra were kept at 150 s while validation spectra were varied from 3 to 150 s by summing different numbers of frames; for urine samples, the calibration spectra were kept at 64 s while the validation spectra were changed from 2 to 64 s. In the prediction using corrected Raman spectra, the prediction error RMSECV c will have a shot-noise related term that decreases with integration time t and a noise-independent term due to other error sources, e.g., imperfect PLS calibration and reference error. This was parameterized as
For each chemical, the constants ␣ and ␤ were calculated.
To study the dependence of prediction error on the sample set size n, PLS cross validation was performed on a randomly selected subgroup of n samples. This was repeated m times to make m ϫ n large ͑Ն1400͒ for all n values. The root-mean-square RMSECV was calculated for each value of n.
Results
A. Spectra
Typical corrected blood serum and urine Raman are shown in Figs. 2A and 2B . Integration times are 150 and 64 s, respectively. Direct Raman spectra (not shown) have the same peaks but different relative intensities across the spectral range.
B. Concentration Predictions
Blood Serum Samples
PLS cross-validation results for blood serum analytes using corrected LCOF Raman spectra are shown in Figs. 3-6 and summarized in Table 2 . Results for total bilirubin (TB), CO 2 , triglyceride, and BUN using corrected spectra are shown in Figs. 3A-3D. Total protein (TP), albumin, and globulin predictions are shown in Fig. 4 . The globulin reference value is a derived quantity (TP minus albumin) rather than a direct measurement. Total cholesterol and cholesterol carried by low-density lipoproteins (LDL) and high-density lipoproteins (HDL) are shown predicted in Fig. 5 . Glucose prediction results are shown in Fig.  6 plotted on the Clarke error grid, the widely used method of evaluating the clinical usefulness of glu- cose predictions. 33 Of the 71 serum spectra, three corresponded to samples that did not come with reference glucose concentrations, so 68 spectra were available. Predictions in zones A and B are considered acceptable, and predictions in zones C, D, and E are potentially dangerous if used in clinical judgment. For comparison, predictions are shown using both direct (open circle) and corrected (filled circle) spectra. The direct spectra have RMSECV d ϭ 15.4 mg͞dl, while the corrected spectra improve to 8.8 mg͞dl. All the 68 samples fall in zones A and B in both cases, but the correction increases the number of As from 57 to 64. After correction, the remaining four samples in zone B are very close to zone A.
Urine Samples
The prediction results of UUN and creatinine in urine samples are shown in Fig. 7 . Using corrected spectra, RMSECV c values of 40 mg͞dl and 4.3 mg͞dl were obtained, respectively. Table 2 show that 11 chemicals in blood serum and two chemicals in urine were quantified above the noise. In most instances, the Ramanbased prediction error was limited by the reference analyzer error. The label "ϫ" in Table 2 indicates RMSECV values that were statistically identical to the reference error [E ref as determined by f test (95% confidence)]. Eight of the 12 analytes with known reference errors fall into this category. (Globulin reference concentrations were not measured directly but rather calculated from the difference of total protein and albumin, whose concentrations were limited by the reference errors; it is reasonable to conclude globulin is also limited by the reference error.) Of those four remaining chemicals, triglyceride's Raman prediction error is only slightly higher (11.5 versus 8.0 mg͞dl), and glucose's is slightly higher than a factor of 2 (8.8 versus 3.8 mg͞dl). Eleven of the 13 analytes exhibited corrected g values greater than 2, which we use as a rough baseline for "useful" predictions.
Discussion
A. Concentration Predictions
Raman Prediction Error Versus Reference Error Figures 3-6 and
Corrected Versus Direct Spectra
As mentioned, Fig. 6 illustrates the improved glucose prediction achieved using corrected spectra. Indicated in Table 2 by "Y," eight of the 13 analytes showed a significant reduction in RMSECV by an f test with 95% confidence level and therefore a positive change in g value ͑⌬g Ͼ 0͒. Total cholesterol showed the biggest improvement, with RMSECV dropping from 9.1 to 4.0 mg͞dl, g increasing from 4.4 to 10.5, and 54 out of 71 individual samples' predictions getting more accurate. Among the other five analytes, as we have pointed out, CO 2 , BUN, and globulin predictions were already limited by reference error and thus should not have improved. The other two analytes, HDL and LDL, will be discussed below. No analyte had a significantly worse RMSECV due to the correction method. The absorptioncorrection processing clearly removed noise from the data and improved the ability of PLS to extract concentration predictions.
General Discussion
HDL and LDL had the smallest g c values, and they showed no improvement ͑⌬g Յ 0͒ when the correction method was used. In both cases, we suspect that the major limitation was the uncertainty of the reference concentrations. HDL and LDL are determined based on the amount of cholesterol the lipoproteins carry. 34 In blood serum HDL, LDL, and very-low-density lipoproteins (VLDL) exchange cholesterol and tryglyceride. The half-life for HDL and LDL retaining cholesterol is only a few days 35 ; as noted, the time interval between the clinical reference measurement and the Raman spectrum measurement was 8 -14 days. For these two analytes, then, it is likely that the reference concentrations were out-of-date by the time of the Raman measurement. Such delays were of course specific to this experiment and do not hamper the method itself; improved prediction accuracy can be expected for LDL and HDL with less time delay and͞or improved calibration. CO 2 , BUN, and TB also exhibited relatively smaller g c values than other chemicals (1.9, 3.3, and 2.8). In these cases, the reason is their relatively low physiological concentration levels compared with the system detection limit. The reference error of CO 2 was 1.9 milliequivalents per liter (mEq͞l) while the mean concentration was 27 mEq͞l. Compared with most of the other chemicals studied, this was a large reference error and probably accounted for the poor g value. The mean concentration of BUN in this sample set was 17.3 mg͞dl, an order of magnitude lower than for most of the other analytes reported. As shown in (17) 9.3 5.1 ϫ 6.8 (9) Y 3.4 550-1800 Globulin 110 (11) 4.1 --130 (11) 0.6 1000-1800 Glucose 8.8 (14) 5 (10) 0 510-1200 LDL* 12.4 (12) 2.7 7.5 11.2 (11) Ϫ0.3 510-1200 a Differences in error levels were assessed by an f test at the 95% confidence level. "ϫ" indicates analytes whose RMSECV c reached the reference error limit ͑8͞13͒. "Y " indicates analytes whose prediction error was significantly reduced by the correction methods ͑8͞13͒. None was significantly increased. Correction also tended to increase g, as shown in the ⌬g column, ranging from 0.9 to 6.1. Ranks of the PLS cross validation are shown together with the RMSECV values in parentheses. Asterisks indicate analytes whose concentrations probably changed substantially between the reference and the Raman measurements. Table 2 , the absolute prediction error ͑1.5 mg͞dl͒ was comparable to that of the other analytes, and at a level that seems roughly conserved, as has also been noticed by Rohleder et al. 7 TB, meanwhile, had such a low mean concentration (0.6 mg͞dl) that the prediction ability was probably due either to an unusually strong Raman cross section or to correlation with some more abundant chemical.
There were several other analytes measured by the blood serum analyzer for which the spectroscopy-PLS combination showed no predictive power. In all cases, the failure is unsurprising. Four of those analytes were monatomic ions (Na
) that have no vibrational spectrum. A fourth was creatinine, which in serum is present at less than 1 mg͞dl levels, lower than all chemicals studied here except for TB, which (as speculated above) probably is not the direct source of Raman bands that correlate with its concentration. The other reported values are enzyme activities, osmolality gap, and ratios of total cholesterol to HDL, all of which would not be likely to show linear correlation with Raman bands.
The prediction error levels obtained here compare favorably with previously published serum results in mid-IR and near-IR absorption and cuvette-based Raman spectroscopy. For instance, the glucose error was 8.8 mg͞dl (150 s integration time) or 11.9 mg͞dl (20 s integration); recently reported glucose experiments include errors of 727 mg͞dl for mid-IR, 14 mg͞dl for NIR, and 1726 mg͞dl for Raman. Rohleder et al. 7 recently published an extensive comparison of prediction errors for multiple analytes across various mid-IR and Raman experiments; for all the analytes we also measured, the errors here are as low or lower, and are obtained in less integration time. To the best of our knowledge, Raman-based measurements of CO 2 , globulin, and TB have not been previously reported in blood serum. Figure 8 plots the prediction quality coefficient g versus the integration time for different chemicals. The data points and error bars were calculated using various sums of individual spectral frames. The error bars at 150 s (for which only one sum was possible) were extrapolated from shorter integration times. The continuous curves are fits to Eq. (3), providing ␣ and ␤ values that permit quantitative estimation of the shot-noise contribution to the total prediction error. Figure 8 and Eq. (3) allow us to identify the characteristic time at which system error contributes equally with shot noise to the total RMSECV. It is defined as
B. Dependence on the Integration Time
For t Ͼ t c , further spectral integration does not greatly improve prediction accuracy. Values of t c for All three plots of RMSECV improve when sample number n increases and plateaus by n ϭ 60. The optimal PLS model rank (number of line shapes used to model the spectra) ranged from 3 to 17 for the analytes in this study. A standard recommendation for calibration is to have a sample number n at least 3 times larger than the rank of the PLS calibration. The sample set sizes here of 71 (blood serum) and 61 (urine) were thus large enough to satisfy this criterion. Figure 9 plots the variation of RMSECV with the sample set size for three blood serum analytes: triglyceride, glucose, and cholesterol. The RMSECV decreased versus n and reached a plateau at approximately n ϭ 60. As discussed above, these limiting RMSECV values are in most cases equivalent to the reference analyzer error. This suggests that increasing the sample set size further is less important than obtaining more accurate reference measurements.
Conclusion
Measurement of multiple key analytes in clinical urine and blood serum samples at physiological concentrations using LCOF Raman spectroscopy has been demonstrated. Most concentrations could be predicted within the accuracy of a clinical reference analyzer using 10 s spectra. Absorption-based correction for variations in LCOF collection efficiency improved most analytes' predictions, showing that the additional white-light transmission measurement was beneficial. We note that the LCOF Raman system lends itself well to high-volume, automated sample analysis, both in geometry and in lack of consumables. quantification of cholesterol, glucose and urea in control serum solutions using searching combination moving window partial least squares regression method with near infrared spectroscopy," Chemom. Intell. Lab. Syst. 82, 90 -96 (2006). 13. S. Kasemsumran, Y. P. Du, K. Maruo, and Y. Ozaki, "Improvement of partial least squares models for in vitro and in vivo Fig. 9 . (Color online) RMSECV versus the sample size n. From top to bottom, as marked: solid points, triglyceride; crosses, glucose; squares, cholesterol. The experimental data points and error bars were calculated using multiple equal-sized subsets of spectra randomly selected from the total sample pool. The integration time is 150 s.
